慢性淋巴细胞白血病离体药物组合效应调查揭示协同药物效应与遗传依赖性
该研究通过分析52例原发性慢性淋巴细胞白血病(CLL)样本的离体药物反应,并借助组学图谱,检测了352对药物组合在多种浓度下的效应。研究确认了B细胞受体(BCR)抑制剂与Bcl-2抑制剂及化疗药物的已知协同作用,并发现BCR抑制剂与阿法替尼的协同作用,归因于阿法替尼通过BLK激活BCR。多种BCR组分抑制剂的组合效应与单药相似;含PI3K抑制剂的组合在IGHV突变CLL中表现出更大的反应异质性。
要点
- 在52例原代CLL样本中检测352对药物组合的离体效应。
- BCR抑制剂与Bcl-2抑制剂及化疗药显示已知协同作用。
- BCR抑制剂与阿法替尼协同,归因于阿法替尼经BLK激活BCR。
核心结论
- 药物组合效应可在原代癌细胞中有效查询,可能有助于药物组合的发现、筛选和临床开发。
研究设计与样本
- 研究分析了52例原发性CLL样本的离体药物反应,样本经组学图谱表征,检测了352对药物组合在多种浓度下的效应。
主要发现
- BCR抑制剂与Bcl-2抑制剂及化疗药物的已知协同作用得到确认。
- 发现BCR抑制剂与阿法替尼的协同作用,归因于阿法替尼通过BLK在BTK和PI3K上游激活BCR。
- 多种BCR组分抑制剂(如BTK、PI3K、SYK)的组合效应与单药相似。
- PI3K和BTK抑制剂与其他药物组合的总体效应相似,但含PI3K抑制剂的组合反应异质性更大,主要见于IGHV突变的CLL,归因于靶点在BCR信号通路中的位置。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug combinations that target critical pathways are a mainstay of cancer care. To improve current approaches to combination treatment of chronic lymphocytic leukemia (CLL) and gain insights into the underlying biology, we studied the effect of 352 drug combination pairs in multiple concentrations by analysing ex vivo drug response of 52 primary CLL samples, which were characterized by "omics" profiling. Known synergistic interactions were confirmed for B-cell receptor (BCR) inhibitors with Bcl-2 inhibitors and with chemotherapeutic drugs, suggesting that this approach can identify clinically useful combinations. Moreover, we uncovered synergistic interactions between BCR inhibitors and afatinib, which we attribute to BCR activation by afatinib through BLK upstream of BTK and PI3K. Combinations of multiple inhibitors of BCR components (e.g., BTK, PI3K, SYK) had effects similar to the single agents. While PI3K and BTK inhibitors produced overall similar effects in combinations with other drugs, we uncovered a larger response heterogeneity of combinations including PI3K inhibitors, predominantly in CLL with mutated IGHV, which we attribute to the target's position within the BCR-signaling pathway. Taken together, our study shows that drug combination effects can be effectively queried in primary cancer cells, which could aid discovery, triage and clinical development of drug combinations.
引用
- Lukas M, Velten B, Sellner L, et al. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. Leukemia. 2020. PMID: 32404973. doi:10.1038/s41375-020-0846-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。